Results 181 to 190 of about 1,016,262 (299)

Dual-targeting proteasome inhibitor ONX-0914 demonstrates potent antiplasmodial activity for malaria treatment. [PDF]

Int J Parasitol Drugs Drug Resist
Van Truong N, Nguyen TK, Thau NS, Chu TH, Sanaullah B, Venkataramaiah C, Han JH, Na SH, Park WS, Chun WJ, No JH, Han ET.   +11 more
europepmc   +1 more source

Epithelial SLC25A20 Deficiency Drives Immunosuppressive Neutrophil Remodeling via ARG1 Palmitoylation to Promote Colorectal Cancer

Advanced Science, EarlyView.
SLC25A20 deficiency in tumor cells compromises mitochondrial LCFA transport, which suppresses FAO and drives compensatory release of palmitic acid‐enriched lipids into the TME. These tumor‐derived palmitic acids are taken up by TANs, promoting ZDHHC18‐catalyzed ARG1 palmitoylation.
Yue Han, Tian‐Yuan Tan, Bin Zhang, Ye‐Bin Fu, Wen Chen, Min‐Hui Yang, Yi‐Qing Wang, Yan‐Qing Ding, Shuang Wang   +8 more
wiley   +1 more source

Depletion of IgG-producing plasma cells in the colon by treatment of proteasome inhibitor ameliorates chronic DSS-induced colitis in mice. [PDF]

Sci Rep
Ebihara S, Kimoto Y, Katsumoto R, Konishi N.   +3 more
europepmc   +1 more source

Mitochondrial Localization of Cx26 Promotes Colorectal Cancer Malignancy and Exposes a Fatal Vulnerability to Drug Targeting

Advanced Science, EarlyView.
Mitochondrial localization of Cx26 emerges as a double‐edged sword in colorectal cancer. PIMT‐mediated methylation of Cx26 promotes its mitochondrial localization and stability. Mitochondrial Cx26 then facilitates ER‐mitochondria communication and Ca2+ signaling, thereby promoting metastatic progression. Bortezomib exploits this malignant adaptation by
Jie Wang, Lu Chen, Jia Qin, Xiaoning Wang, Sunlan Ye, Ning An, Mei Bai, Yan Shen, Xuefeng Wu, Qiang Xu   +9 more
wiley   +1 more source

RETRACTION: Delanzomib, a Novel Proteasome Inhibitor, Sensitizes Breast Cancer Cells to Doxorubicin-Induced Apoptosis. [PDF]

Thorac Cancer
europepmc   +1 more source

[Corrigendum] Dual targeting of glioblastoma multiforme with a proteasome inhibitor (Velcade) and a phosphatidylinositol 3‑kinase inhibitor (ZSTK474). [PDF]

Int J Oncol
Lin L, Gaut D, Hu K, Yan H, Yin D, Koeffler PH.   +5 more
europepmc   +1 more source

Bacteria‐Derived 1‐Allylpiperazine Alleviates Symptoms of Parkinson's Disease Model by Promoting Autophagy

Advanced Science, EarlyView.
Parkinson's disease currently has no disease‐modifying therapies. In Caenorhabditis elegans, Escherichia coli E8 alleviates α‐synuclein‐provoked PD‐related defects through its bioactive metabolite 1‐ALPP, which combats PD by triggering AMPK/mTOR/HLH‐30‐dependent autophagy and suppressing α‐synuclein LLPS‐mediated fibrillization.
Mingqin Qu, Xinyuan Zhang, Xinyi Chen, Jiaxin Shi, Meng Xu, Fuhao Wang, Jinling Lv, Jiaman Sun, Weiyi Niu, Zihan Liu, Li Li, Fufeng Liu, Xiangming Wang   +12 more
wiley   +1 more source

Safety and pharmacokinetics of GSK3494245, a highly selective Leishmaniasis kinetoplastid proteasome inhibitor for the treatment of visceral leishmaniasis: A Phase 1, randomized, single ascending dose escalation study in healthy participants. [PDF]

PLoS Negl Trop Dis
Moodley M, Kostapanos M, Iavarone L, Bracher M, Lavezzi SM, Davy M, Singh P, Bhat R, Wong D, Sharma H, Tan LK, Miles TJ.   +11 more
europepmc   +1 more source

Orthogonal Light‐ and Enzyme‐Triggered and‐Gate Prodrugs for Senolytic Therapy

Advanced Science, EarlyView.
An orthogonal AND‐gate prodrug platform combines 390 nm near‐UV photocleavage with SA‐β‐gal activation to control payload release in senescent cells. Its modular architecture enables 4‐MU fluorescence, doxorubicin‐mediated cytotoxicity, and ARV‐771‐driven BRD4 degradation, supporting stimulus‐controlled senolytic design in cellular and organoid models.
Mengyang Chang, Kaixue Zhang, Junwei Wang, Fangchao Bi, Zhuoxin Dai, Miao Yang, Ming Liu, Huanzhi Peng, Franklin Zhang, Yuan Guo, Jigang Dai, Quanxing Liu, Wei Wang   +12 more
wiley   +1 more source

Real-world outcomes in patients with relapsed and refractory multiple myeloma with prior proteasome inhibitor and lenalidomide exposure: A single-center study in Sweden. [PDF]

Clin Hematol Int
Luong V, Kashif M, Uttervall K, Bohlin A, Öster Fernström A, Qu Y, Lee S, Mendes J, Van Hoorenbeeck S, Hellqvist Franck E, He J, Alici E, Lund J.   +12 more
europepmc   +1 more source